Royalty Pharma (RPRX) Q1 2026 Earnings
Royalty Pharma reported Q1 2026 revenue of $925.0M (+62.8% YoY), beat analyst consensus of $881.7M by $43.3M. Diluted EPS came in at $1.30 (+22.6% YoY), beat the $1.22 consensus by $0.08. Royalty Pharma reports across 2 business segments, led by Marketed Royalties and Development-Stage Royalties & Funding.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Royalty Pharma's Q1 2026 earnings report.
Royalty Pharma (RPRX) reported Q1 2026 earnings on May 6, 2026 before market open.
Royalty Pharma reported revenue of $925.0M and diluted EPS of $1.30 for Q1 2026.
Revenue beat the consensus estimate of $881.7M by $43.3M. EPS beat the consensus estimate of $1.22 by $0.08.
Compared to the same quarter a year prior, revenue grew 62.8% from $568.2M a year earlier and diluted EPS grew 22.6% from $1.06.
You can read the 8-K earnings release (0001802768-26-000008) and the 10-Q periodic report (0001802768-26-000009) directly on SEC EDGAR. The filing index links above go to sec.gov.